Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: Systematic review and meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 17712-17720

  Qiao, Li ^a   Xu, Chengshan ^a   Li, Xinji ^a   Li, Fei ^a   Liu, Wei ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Dysfunction; Meta analysis; Mortality; Operative; Organ; Surgical

Indexed keywords

CALCIUM SENSITIZER; CATECHOLAMINE; DOBUTAMINE; LEVOSIMENDAN; TROPONIN;

ATRIAL FIBRILLATION; CONGESTIVE HEART FAILURE; HIGH RISK PATIENT; HUMAN; INTERNAL VALIDITY; META ANALYSIS (TOPIC); MORBIDITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

EID: 84949633216     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. [1] Bone RC, Sibbald WJ and Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101: 1481-1483.
2. [2] Soares M, Feres GA and Salluh JI. Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumorlysis syndrome. Clinics (Sao Paulo) 2009; 64: 479-481.
3. [3] Mizock BA. The multiple organ dysfunction syndrome. Dis Mon 2009; 55: 476-526.
4. [4] Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin 2011; 27: 1673-1682.
5. [5] Juni P, Altman DG and Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
6. [6] Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
7. [7] Villar J, Mackey ME, Carroli G and Donner A. Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med 2001; 20: 3635-3647.
8. [8] Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002; 21: 1575-1600.
9. [9] Bradburn MJ, Deeks JJ, Berlin JA and Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
10. [10] Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
11. [11] Hatala R, Keitz S, Wyer P and Guyatt G. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005; 172: 661-665.
12. [12] Glasziou PP and Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med 2002; 21: 1503-1511.
13. [13] Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O, Bascuas B, Perez-Paz J and Ginesta V. [Hemodynamic effects of levosimendan following cardiac surgery]. Rev Esp Anestesiol Reanim 2005; 52: 389-394.
14. [14] De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S and Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008; 22: 699-705.
15. [15] Jarvela K, Maaranen P, Sisto T and Ruokonen E. Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth 2008; 22: 693-698.
16. [16] Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, Tanus E and del Mazo CD. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol 2008; 61: 471-479.
17. [17] Missant C, Rex S, Segers P and Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35: 707-715.
18. [18] Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, Ginesta V, Rubio J, Garcia-Bengoechea JB and Gonzalez-Juanatey JR. [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol 2006; 59: 338-345.
19. [19] du Toit E, Hofmann D, McCarthy J and Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001; 86: 81-87.
20. [20] Hung PT and Galin MA. [Trabecular microsurgery in glaucoma]. Taiwan Yi Xue Hui Za Zhi 1975; 74: 697-701.
21. [21] De Hert SG, Lorsomradee S, Cromheecke S and Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766-773.
22. [22] Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M and Pietropaoli P. Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth 2006; 96: 694-700.
23. [23] Shah B, Sharma P, Brahmbhatt A, Shah R, Rathod B, Shastri N, Patel J and Malhotra A. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian J Pharmacol 2014; 46: 29-34.
24. [24] Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L and Burzotta F. A simple hint to improve Robinson and Dickersin’s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34: 224-225; author reply 225.
25. [25] Kompan L, Kremzar B, Gadzijev E and Prosek M. Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. Intensive Care Med 1999; 25: 157-161.
26. [26] Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, De Santis V, Tritapepe L and Landoni G. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009; 23: 474-478.
27. [27] Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP and Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
28. [28] Cleland JG, Freemantle N, Coletta AP and Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-110.
29. [29] Thackray S, Easthaugh J, Freemantle N and Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002; 4: 515-529.
30. [30] Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B and Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008; 108: 979-987.